The evolution of lung cancer treatment is an example of new perspectives in clinical oncology. Genomically determined targeted therapy of non-small cell lung cancer (NSCLC) is developing very rapidly with the gradual identification of new target structures and the concomitant development of innovative drugs are a great promise for the future. The historical development of systemic treatment of NSCLC is a model example of the path to accurate (precise) treatment. The innovation of the treatment has led to the shift from (non-targeted) cytostatic treatment to targeted therapy and immunotherapy. The targeted treatment and immunotherapy with checkpoint inhibitors have led to breakthrough prolongation of survival in patients with advanced NSCLC. According to a recent European Society for Medical Oncology (ESMO) recommendation, NSCLC is therefore one of the diagnoses where an examination using the next-generation sequencing panel should be performed as a standard.

Download full-text PDF

Source

Publication Analysis

Top Keywords

lung cancer
12
cancer treatment
8
targeted therapy
8
treatment
7
future lung
4
treatment evolution
4
evolution lung
4
treatment example
4
example perspectives
4
perspectives clinical
4

Similar Publications

This study aims to investigate the expression of seven cancer testis antigens (MAGE-A1, MAGE-A4, MAGE-A10, MAGE-A11, PRAME, NY-ESO-1 and KK-LC-1) in pan squamous cell carcinoma and their prognostic value, thus assessing the potential of these CTAs as immunotherapeutic targets. The protein expression of these CTAs was evaluated by immunohistochemistry in 60 lung squamous cell carcinoma (LUSC), 62 esophageal squamous cell carcinoma (ESCA) and 62 head and neck squamous cell carcinoma (HNSC). The relationship between CTAs expression and progression-free survival (PFS) was assessed.

View Article and Find Full Text PDF

We demonstrate that performing anatomical pulmonary resection by video-assisted thoracoscopic surgery without staplers or energy devices is feasible. This technique is an alternative for surgeons with limited access to expensive technologies.

View Article and Find Full Text PDF

Diagnosis of lung cancer using salivary miRNAs expression and clinical characteristics.

BMC Pulm Med

January 2025

Universal Scientific Education and Research Network (USERN), Tehran, Iran.

Objective: Lung cancer (LC), the primary cause for cancer-related death globally is a diverse illness with various characteristics. Saliva is a readily available biofluid and a rich source of miRNA. It can be collected non-invasively as well as transported and stored easily.

View Article and Find Full Text PDF

The association between Chlamydia pneumoniae infection and prognosis in lung cancer patients: a prospective study.

BMC Infect Dis

January 2025

Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China.

Background: The prognostic value of Chlamydia pneumoniae (Cpn) infection in postoperative lung cancer patients remains unclear. This study aimed to evaluate the association between Cpn infection and survival in lung cancer patients.

Methods: This study included 309 newly diagnosed primary lung cancer patients from three hospitals in Fuzhou, China.

View Article and Find Full Text PDF

The role of Box A of HMGB1 in producing γH2AX associated DNA breaks in lung cancer.

Sci Rep

January 2025

Center of Excellence in Molecular Genetics of Cancer and Human Diseases, Department of Anatomy, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

An ideal chemotherapeutic agent damages DNA, specifically in cancer cells, without harming normal cells. Recently, we used Box A of HMGB1 plasmid as molecular scissors to produce DNA gaps in normal cells. The DNA gap relieves DNA tension and increases DNA strength, preventing DNA double-strand breaks (DSBs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!